Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors

CRISPR knock out CTLA-4 enhances the anti-tumor activity of cytotoxic T lymphocytes

(2017) Long Shi et al.   GENE

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy

(2017) Paul A. Beavis et al.   JOURNAL OF CLINICAL INVESTIGATION

A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy

(2017) Erhao Zhang et al.   Journal of Hematology & Oncology

Chimeric antigen receptor T cells: a novel therapy for solid tumors

(2017) Shengnan Yu et al.   Journal of Hematology & Oncology

Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells

(2017) Lynsey M. Whilding et al.   MOLECULAR THERAPY

In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers

(2017) Tyrel T. Smith et al.   Nature Nanotechnology

Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy

(2017) Hengfeng Yuan et al.   Nature Nanotechnology

An oxygen sensitive self-decision making engineered CAR T-cell

(2017) Alexandre Juillerat et al.   Scientific Reports

Myeloid-Derived Suppressor Cells

(2017) Dmitry I. Gabrilovich   Cancer Immunology Research

Overexpression of heparanase enhances T lymphocyte activities and intensifies the inflammatory response in a model of murine rheumatoid arthritis

(2017) Andreas Digre et al.   Scientific Reports

Extracellular matrix structure

(2016) Achilleas D. Theocharis et al.   ADVANCED DRUG DELIVERY REVIEWS

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells

(2016) Ilaria Marigo et al.   CANCER CELL

Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death

(2016) M. J. Scheffel et al.   CANCER RESEARCH

Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells

(2016) Michael Boice et al.   CELL

L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity

(2016) Roger Geiger et al.   CELL

Immunosuppressive activities of adenosine in cancer

(2016) Bertrand Allard et al.   CURRENT OPINION IN PHARMACOLOGY

Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors

(2016) Chuan Jin et al.   Immunotherapy

Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism

(2016) Wei Yang et al.   NATURE

Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps

(2016) Gregory L. Beatty et al.   PHARMACOLOGY & THERAPEUTICS

CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients

(2016) Shu Su et al.   Scientific Reports

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs

(2015) Soranobu Ninomiya et al.   BLOOD

Shifting the Evolving CAR T Cell Platform into Higher Gear

(2015) Daniel R. Holohan et al.   CANCER CELL

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

(2015) Zeguo Zhao et al.   CANCER CELL

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Translational Implications of Tumor Heterogeneity

(2015) M. Jamal-Hanjani et al.   CLINICAL CANCER RESEARCH

TRUCKs: the fourth generation of CARs

(2015) Markus Chmielewski et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected

(2015) Douglas Marvel et al.   JOURNAL OF CLINICAL INVESTIGATION

Coexpressed Catalase Protects Chimeric Antigen Receptor–Redirected T Cells as well as Bystander Cells from Oxidative Stress–Induced Loss of Antitumor Activity

(2015) Maarten A. Ligtenberg et al.   JOURNAL OF IMMUNOLOGY

CAR-T field booms as next-generation platforms attract big players

(2015) Chris Morrison   NATURE BIOTECHNOLOGY

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

(2015) Xiaojuan Liu et al.   NATURE MEDICINE

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes

(2015) Ignazio Caruana et al.   NATURE MEDICINE

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer

(2015) P. H. Lizotte et al.   Nature Nanotechnology

The pharmacology of second-generation chimeric antigen receptors

(2015) Sjoukje J. C. van der Stegen et al.   NATURE REVIEWS DRUG DISCOVERY

Adoptive cell transfer as personalized immunotherapy for human cancer

(2015) S. A. Rosenberg et al.   SCIENCE

Adoptive cellular therapy: A race to the finish line

(2015) Carl H. June et al.   Science Translational Medicine

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

(2015) David L. Porter et al.   Science Translational Medicine

Engineering CAR-T cells: Design concepts

(2015) Shivani Srivastava et al.   TRENDS IN IMMUNOLOGY

Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy

(2015) Xiang-Jun Tang et al.   Oncotarget

Oncolytic viruses: From bench to bedside with a focus on safety

(2015) Pascal RA Buijs et al.   Human Vaccines & Immunotherapeutics

Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors

(2015) Nobuhiro Nishio et al.   OncoImmunology

Chimeric antigen receptor–engineered T cells as oncolytic virus carriers

(2015) Heather VanSeggelen et al.   Molecular Therapy-Oncolytics

Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles

(2014) Marina Colombo et al.   Annual Review of Cell and Developmental Biology

VISTA Is an Immune Checkpoint Molecule for Human T Cells

(2014) J. L. Lines et al.   CANCER RESEARCH

Evolution of the Cancer Stem Cell Model

(2014) Antonija Kreso et al.   Cell Stem Cell

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment

(2014) Daniel Ackerman et al.   TRENDS IN CELL BIOLOGY

The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target

(2013) A. Neil Barclay et al.   Annual Review of Immunology

Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology

(2013) Michael Kalos et al.   IMMUNITY

Myeloid-derived suppressor cells in cancer: recent progress and prospects

(2013) Yazan S Khaled et al.   IMMUNOLOGY AND CELL BIOLOGY

Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery

(2013) Xinping Fu et al.   INTERNATIONAL JOURNAL OF CANCER

The tumor microenvironment at a glance

(2013) F. R. Balkwill et al.   JOURNAL OF CELL SCIENCE

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells

(2013) Petra C Schuberth et al.   Journal of Translational Medicine

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

(2013) C. Feig et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Basic Principles of Chimeric Antigen Receptor Design

(2013) Michel Sadelain et al.   Cancer Discovery

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

(2012) H. J. Pegram et al.   BLOOD

CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest

(2012) E Sick et al.   BRITISH JOURNAL OF PHARMACOLOGY

The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications

(2012) Mark P Chao et al.   CURRENT OPINION IN IMMUNOLOGY

The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy

(2012) Christine Pasero et al.   CURRENT OPINION IN PHARMACOLOGY

Constitutive Clathrin-mediated Endocytosis of CTLA-4 Persists during T Cell Activation

(2012) Omar S. Qureshi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor

(2012) Megan E. Prosser et al.   MOLECULAR IMMUNOLOGY

CD73: a potent suppressor of antitumor immune responses

(2012) Paul. A. Beavis et al.   TRENDS IN IMMUNOLOGY

CAR–T cells and solid tumors: tuning T cells to challenge an inveterate foe

(2012) David E. Gilham et al.   TRENDS IN MOLECULAR MEDICINE

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor

(2011) E. K. Moon et al.   CLINICAL CANCER RESEARCH

The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation

(2011) Marcos W. Steinberg et al.   IMMUNOLOGICAL REVIEWS

VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses

(2011) Li Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Regulation of Macrophage Arginase Expression and Tumor Growth by the Ron Receptor Tyrosine Kinase

(2011) D. R. Sharda et al.   JOURNAL OF IMMUNOLOGY

High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis

(2011) E Launay et al.   LEUKEMIA

Improving Adoptive T Cell Therapy by Targeting and Controlling IL-12 Expression to the Tumor Environment

(2011) Ling Zhang et al.   MOLECULAR THERAPY

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

The cancer stem cell: premises, promises and challenges

(2011) Hans Clevers   NATURE MEDICINE

Foxp3+ follicular regulatory T cells control the germinal center response

(2011) Michelle A Linterman et al.   NATURE MEDICINE

A multifunctional core–shell nanoparticle for dendritic cell-based cancer immunotherapy

(2011) Nam-Hyuk Cho et al.   Nature Nanotechnology

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD73: A Novel Target for Cancer Immunotherapy

(2010) B. Zhang   CANCER RESEARCH

Acquired TNFRSF14 Mutations in Follicular Lymphoma Are Associated with Worse Prognosis

(2010) K.-J. J. Cheung et al.   CANCER RESEARCH

HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment

(2010) Cesar A. Corzo et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Tumor-Conditioned Macrophages Secrete Migration-Stimulating Factor: A New Marker for M2-Polarization, Influencing Tumor Cell Motility

(2010) G. Solinas et al.   JOURNAL OF IMMUNOLOGY

Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b

(2010) John A. Craddock et al.   JOURNAL OF IMMUNOTHERAPY

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

(2010) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model

(2009) A. Di Stasi et al.   BLOOD

Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment

(2009) H. Harlin et al.   CANCER RESEARCH

The promise and potential pitfalls of chimeric antigen receptors

(2009) Michel Sadelain et al.   CURRENT OPINION IN IMMUNOLOGY

Genetic Manipulation of Tumor-specific Cytotoxic T Lymphocytes to Restore Responsiveness to IL-7

(2009) Juan F Vera et al.   MOLECULAR THERAPY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Regulatory T Cells and Immune Tolerance

(2008) Shimon Sakaguchi et al.   CELL

The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages

(2008) Paola Allavena et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-?? Receptor

(2008) Aaron E. Foster et al.   JOURNAL OF IMMUNOTHERAPY

Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond

(2008) Vadivel Ganapathy et al.   PHARMACOLOGY & THERAPEUTICS